Based on the above findings about NF-κB signaling, a network pharmacology study of Liu et al. (2022) showed that the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt)/NF-κB/TNF-α/IL-1β pathway was the molecular mechanism of KXC to interfere DKD, which was confirmed by in vitro and in vivo experiments. The gene discussed is NFKB1; the disease is diabetic kidney disease.